UMich logo

 

 

 

Swiecicki WhiteCoatInvestigator: Dr. Paul Swiecicki

Disease: Thyroid Cancer

Research Description: Thyroid cancer is the sixteenth most common malignancy in the world. Although most patients are cured with a combination of surgery, radioactive iodine therapy, and thyroid stimulating hormone suppression, approximately 15% of patients will develop treatment-resistant (refractory) disease. In the U.S. alone, roughly 9,400 patients fall into this category each year. Currently, the treatment options for refractory thyroid cancer are limited and are mostly palliative in intent. Previous molecular and genomic analyses in thyroid cancer have identified potential targets for repurposed therapeutics. The research team looked at other cancers with similar targets, and saw they responded to a combination of the generic drugs cyclophosphamide and sirolimus. The team tried this combination in patients with aggressive thyroid cancer and anecdotally had success. They now propose a clinical trial repurposing cyclophosphamide and sirolimus to evaluate if this is a safe and effective combination therapy to treat refractory thyroid cancer. This is of profound interest given the lack of current treatment options in the patient population and potential healthcare cost savings with this repurposed combination.

CWR funding role: Participating funder

CWR funding start date: January 2018

 

Sign up for our eNewsletter today!

 

First Name




Thanks for your patience while the donation form loads!

Cures Within Reach

info@cureswithinreach.org

All funds donated to Cures Within Reach may be tax deductible for federal income tax purposes.  CWR is recognized by the IRS as a 501(c)3 tax-exempt not-for-profit organization, tax ID 20-3620169.

 

Friday the 20th. Copyright 2018 Cures Within Reach.